



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C07K 7/06, 7/08, 7/10 C07K 13/00, 15/00		A1	(11) International Publication Number: WO 87/ 00528 (43) International Publication Date: 29 January 1987 (29.01.87)		
(21) International Application Number: PCT/US86/01505 (22) International Filing Date: 17 July 1986 (17.07.86)		(74) Agents: WATT, Phillip, H. et al.; Fitch, Even, Tabin & Flannery, Room 900, 135 South LaSalle Street, Chicago, IL 60603 (US).			
(31) Priority Application Numbers: 756,866 784,436		(81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).			
(32) Priority Dates: 18 July 1985 (18.07.85) 3 October 1985 (03.10.85)					
(33) Priority Country: US		Published <i>With international search report.</i>			
<p>(71) Applicant: THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).</p> <p>(72) Inventors: LING, Nicholas, Chai-Kwan ; 5324 Bloch Street, San Diego, CA 92122 (US). YING, Shao-Yao ; 3305 Willard Street, San Diego, CA 92122 (US). ESCH, Fred, Stephen ; 2929 Fire Mountain Drive, #63, Oceanside, CA 92057 (US). GUILLEMIN, Roger, Charles, Louis ; 7316 Encelia Drive, La Jolla, CA 92037 (US).</p>					
(54) Title: INHIBIN AND METHOD OF PURIFYING SAME					
(57) Abstract					
<p>Two 32,000-dalton proteins with inhibin activity were isolated from porcine follicular fluid using heparin-Sepharose affinity chromatography, followed by gel filtration on Sephadryl S-200 and then four steps of reverse-phase high-performance liquid chromatography. Each isolated molecule is composed of two chains having molecular weights of about 18,000 and about 14,000 daltons, respectively, which are bound together by disulfide bonding. Microsequencing revealed the NH₂-terminal portion of the 18K chain of both to be Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val, of one of the 14K chains to be Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp, and of the other 14K chain to be Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro. Both proteins have now been completely characterized, each having a first chain 134 residues long linked by disulfide bonding to a second chain 116 or 115 residues long. The first chain is believed to be glycosylated, which accounts for the disparity between the number of residues and the apparent molecular weight of 18K. These 32K proteins specifically inhibit basal secretion of FSH, but not of LH, in a rat anterior pituitary monolayer culture system. The half-maximal effective dose of one is 450 pg/ml and of the other is 900 pg/ml.</p>					

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	GA Gabon	MR Mauritania
AU Australia	GB United Kingdom	MW Malawi
BB Barbados	HU Hungary	NL Netherlands
BE Belgium	IT Italy	NO Norway
BG Bulgaria	JP Japan	RO Romania
BR Brazil	KP Democratic People's Republic of Korea	SD Sudan
CF Central African Republic	KR Republic of Korea	SE Sweden
CG Congo	LI Liechtenstein	SN Senegal
CH Switzerland	LK Sri Lanka	SU Soviet Union
CM Cameroun	LU Luxembourg	TD Chad
DE Germany, Federal Republic of	MC Monaco	TG Togo
DK Denmark	MG Madagascar	US United States of America
FI Finland	ML Mali	

-1-

INHIBIN AND METHOD OF PURIFYING SAME

The present invention relates to a protein having inhibin activity isolated substantially to homogeneity from bodily material obtained from porcine animals. The invention also relates to a method of purifying porcine inhibin.

BACKGROUND OF THE INVENTION

The concept of inhibin as a water-soluble substance produced in the gonad but acting specifically at the pituitary level to inhibit the secretion of follicle-stimulating hormone (FSH) was postulated by McCullagh in 1932 (Science, 76, 19-20). Such preferential regulation of the gonadotropin secretion has generated a great deal of interest and has prompted many laboratories in the past fifty years to attempt to isolate and characterize this substance from extracts of testis, spermatozoa, rete testis fluid, seminal plasma and ovarian follicular fluid, using various bioassays. Although many reports have appeared in the literature claiming the purification of inhibin-like material with molecular weights ranging from 5,000 to 100,000 daltons, subsequent studies have shown that these substances were either not homogenous or did not have the high specific activity expected of true inhibin (de Jong, Molecular & Cellular Endocrin., 13, 1-10 (1979)). Materials having inhibin activity may be used to regulate fertility in mammalian animals, particularly male animals.

SUMMARY OF THE INVENTION

In accordance with the present invention, two proteins both having a molecular weight of about 32,000 daltons and having inhibin activity have been successfully isolated from porcine follicular fluid. These two proteins have been completely characterized using microsequencing and molecular biological methods.

-2-

The proteins were isolated to substantial homogeneity from material obtained from the bodies of porcine animals and are hereinafter referred to as Protein A and Protein B. Each protein has a molecular weight of about 32,000 daltons (32K) and is composed of two polypeptide chains having molecular weights of 18,000 and 14,000 daltons, respectively, the chains being linked together in the biologically active protein by disulfide bonding. Microsequencing showed that the amino-terminal 5 amino acid residue sequence of the 18,000 dalton (18K) chain of both proteins was Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val and that the first six residues of 10 both amino-terminals of the 14,000 dalton (14K) chains were the same, namely Gly-Leu-Glu-Cys-Asp-Gly. It was also ascertained that the first ten residues of the 14K 15 chain of Protein B were Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu. Proteins A and B have now been completely characterized as a result of further microsequencing and 20 the use of molecular biological techniques. Each 32K protein exhibits inhibin activity in that it specifically inhibits basal secretion of FSH but does not inhibit basal secretion of luteinizing hormone (LH).
The individual chains are not biologically active.

25 Purification of porcine inhibin to substantial homogeneity, i.e., about 90% by weight of total protein in the fraction, was achieved through a combination of protein separation procedures including heparin-Sepharose affinity chromatography, gel filtration and reverse-phase, high-performance liquid chromatography (RP-HPLC).

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows chromatograms representing initial steps of purifications of inhibin proteins from 30 porcine follicular fluid (PFF) under conditions described as follows:

(a) Heparin-Sepharose affinity chromatography of PFF. The inhibin protein was eluted with 1 M NaCl in 0.01 M Tris-HCl, pH 7.

-3-

(b) Sephadryl S-200 gel filtration of the PFF inhibin proteins. The effluent fractions indicated by the solid bar near the bottom of Figure 1a were pooled, dialyzed and then divided into eight equal portions for this gel filtration. The profile from one of the columns is indicative of each column and is shown.

5

(c) RP-HPLC purification of the inhibin proteins recovered from gel filtration. The components of the active region from the gel filtration, as determined by in vitro bioassay and designated by the solid bar in Figure 1b, were pooled, lyophilized and, after dissolving in 0.2 N acetic acid, applied directly onto a Vydac C4 column and eluted with the indicated gradient of acetonitrile in the TEAP buffer system at 9 ml/3 min. Two inhibin proteins, Proteins A and B, indicated by the solid bars in Figure 1c, were recovered.

10

15

FIGURE 2 shows chromatograms of RP-HPLC purification of inhibin Protein B as follows:

20

(a) The active fractions designated by the solid bar under B in Fig. 1c were pooled and, after being diluted to 3 times their original volume, applied directly onto a Vydac C4 column and eluted with the indicated gradient of acetonitrile in trifluoroacetic acid (TFA) buffer system at 9 ml/3 min.

25

(b) The active material denoted by the solid bar in Figure 2a was pooled, diluted to 3 times its original volume and likewise purified on a Vydac Phenyl column with the indicated gradient of acetonitrile in triethylammonium phosphate (TEAP) buffer system at 2 ml/2 min.

30

35

(c) The active material accumulated from a number of columns identical to that represented by the chromatogram of Figure 2b was pooled and concentrated on an Aquapore RP-300 column with the indicated gradient of acetonitrile in the TFA buffer system at 0.5 ml/min.

FIGURE 3 shows actual electrophoretic results of sodium dodecylsulfate-polyacrylamide gel

-4-

electrophoresis (SDS-PAGE) analysis of the purified inhibin Protein B as follows:

(a) Analysis of Protein B under non-reducing condition.

5 (b) Analysis of Protein B under reducing condition. The molecular weight standards are indicated on the left.

10 FIGURE 4 shows dose-response curves of the purified inhibin Protein B (O), as well as the crude PFF standard (Δ) on the basal secretion of FSH and LH from rat anterior pituitary cell cultures. The crude PFF standard was a charcoal-stripped and 40% saturated ammonium sulfate precipitate of PFF, Schwartz, N. et al. Proc. Natl. Acad. Sci. USA 74 5721-5724 (1977).

15 FIGURE 5 shows chromatograms of RP-HPLC purification of inhibin Protein A as follows:

20 (a) The active fractions designated by the solid bar under A in Fig. 1c were pooled and, after being diluted to 3 times their original volume, applied directly onto a Vydac C4 column and eluted with the indicated gradient of acetonitrile in trifluoroacetic acid (TFA) buffer system at 9 ml/3 min.

25 (b) The active material denoted by the solid bar in Figure 5a was pooled, diluted to 3 times its original volume and likewise purified on a Vydac Phenyl column with the indicated gradient of acetonitrile in triethylammonium phosphate (TEAP) buffer system at 2 ml/2 min.

30 (c) The active material accumulated from a number of columns identical to that represented by the chromatogram of Figure 5b was pooled and concentrated on an Aquapore RP-300 column with the indicated gradient of acetonitrile in the TFA buffer system at 0.5 ml/min.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

35 Using a multi-step procedure, two 32,000 dalton peptides were isolated to substantial homogeneity from porcine follicular fluid (PFF). Each protein (Protein A

-5-

and Protein B) is composed of two chains of 18K and 14K, respectively, and the chains of the intact molecule are held together by disulfide bonding, the linkage between the chains being necessary for biological activity. An amino acid analysis of the total protein has been performed for each, and the amino acid residue sequence of the amino-terminus of each chain has been determined by microsequencing. The amino-terminal sequence of the 18K chain of each protein was found to be: Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val. As a result of further work, it is believed that both 18K chains have exactly the same sequence of 134 amino acid residues and have a free acid C-terminus.

Microsequencing initially showed that the amino-terminal sequences of the 14K chains of the first six residues of both chains were the same and that the first ten residues of the 14K chain of Protein B were Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu. Further sequencing showed that the next 15 residues were X_{11} - X_{12} -Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu- X_{23} -Gly-Trp, with X_{11} possibly being Ser, with X_{12} likely being Cys and with X_{23} being Ile or Leu. Later it was determined that both X_{11} and X_{12} were Cys and that X_{23} was Ile. The ability to sequence the chains demonstrates that the protein has been purified to at least about 90% by weight of total protein as do the sharp elution peaks of the protein in the final chromatographic purification step.

The C-termini of all three chains are free acid. Further microsequencing showed that the N-terminus of the 14K chain of Protein A has the following sequence: Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro.

Protein A has now been completely characterized and found to include a 134-residue chain (the 18K chain)

-6-

that is linked by one or more disulfide bridges to a 116-residue chain (the 14K chain) which appears to include at least one internal disulfide bridge.

Protein B has the same 18K chain linked to a homologous 5 14K chain.

Each 32K protein is acidic, having a pKa of 4.8, and is generally soluble in aqueous media. Each is glycosylated to a limited extent, as determined by limited affinity to concanavalin A. Each 32K protein 10 exhibits inhibin activity in that it specifically inhibits basal secretion of FSH in a rat anterior pituitary monolayer culture system. Protein B exhibits a half-maximal effective dose of 450 pg/ml, as calculated by the computer program BIOPROG, and Protein 15 A exhibits an ED₅₀ of 900 pg/ml. Each 32K protein is useful for regulating fertility of mammalian animals, particularly males.

Each 32K protein has apparent similarities to a 56,000 dalton (56K) protein isolated from bovine 20 follicular fluid, a protein composed of two chains of molecular weights 44,000 and 14,000 daltons (44K and 14K) bound together by disulfide bonds. The first three amino-terminal residues of the 44K bovine chain reported by Robertson et al., Bio. Chem. Biophys. Res. Commun. 25 176 220-226 (1985) are different from either of the two chains of either of the 32K porcine proteins that were isolated, but the second and third residues of the 14K chain of the 56K bovine peptide are identical to those of the 14K chain of both of the 32K porcine peptides. 30 The full relationship, if any, between the 32K porcine proteins and the 56K bovine protein is not known at this time.

Each 32K protein is definitely different from the "alpha-inhibins" Ramasharma, K. et al. Science 223, 35 1199-1201 (1984); Li, C. H. et al., Proc. Natl. Acad. Sci. USA 82 4041-4044 (1985) and "beta-inhibin" Seidah, N. FEBS Letter 175 349-354 (1985) recently isolated and

-7-

characterized from human seminal plasma.
"Alpha-inhibins" are reported to be single-chain polypeptides all derived from a 92-amino-acid-residue parent molecule. However, neither a synthetic replicate 5 of the 31-amino-acid NH₂-terminal fragment of alpha-inhibin-52 nor the native product inhibited the basal FSH-releasing activity in the rat anterior pituitary cell culture, Yamashiro, D. et al., Proc. Natl. Acad. Sci. USA 81 5349-5402 (1984). "Beta-Inhibin" 10 is described as a single-chain polypeptide with 94 amino acid residues, with the bioactive core allegedly residing at the COOH-terminal 67-94 fragment, Arbatti,N. et al. FEBS Letters, 181, 57-63 (1985). This fragment has been synthesized, but it is found to be inactive, up 15 to a concentration of 5 µg/ml, to inhibit the basal secretion of FSH in the rat anterior pituitary cell culture assay. The bioassay methods (for "inhibin activity") used in these two laboratories, Ramasharma et al. supra. and Li et al. supra., are substantially 20 different from those described herein.

In an inhibin purification procedure according to the invention, porcine inhibin is isolated from crude extract material obtained from a porcine animal body, specifically porcine follicular fluid (PFF) although 25 other appropriate bodily extracts might be used, by successive purification procedures that include heparin-Sepharose affinity chromatography, gel filtration and at least one and preferably several RP-HPLCs of different conditions of stationary phase 30 and/or mobile phase. The same procedure is useful in obtaining a desired mammalian inhibin protein from a crude extract resulting from recombinant DNA processes.

In the preferred procedure by which porcine inhibin was first isolated to substantial purity, PFF 35 was first purified by heparin-Sepharose affinity chromatography, next by gel filtration on Sephadryl S-200 gel and then with four successive RP-HPLCs using

-8-

different mobile phase gradients and/or derivatized silica supports. Preferably stationary phases having relatively low hydrophobicity are used, with C3-C8 columns being preferred and C3-C5 and phenyl columns being particularly preferred. Solute specificity of the mobile phase is preferably adjusted by varying the concentration of an organic component, particularly acetonitrile. Although a single RP-HPLC fractionation significantly increases the purity relative to the gel-filtrated material, two or more, and preferably four, RP-HPLC purifications are generally performed subsequent to successive treatment by heparin-Sepharose chromatography and gel filtration.

The starting material for the procedure was frozen PFF that was procured from J.R. Scientific, Woodland, CA. Approximately 18 liters of such frozen PFF were processed in 250 ml batches to isolate the inhibin product. The first step of the purification was heparin-Sepharose affinity chromatography, in which the protein is adsorbed to the Sepharose-bound heparin moieties under application conditions, and the adsorbed inhibin material is recovered by 1M NaCl elution. This step greatly expedites the purification procedure for crude extracts because it allows a relatively large volume of a crude extract, such as PFF, to be processed fairly rapidly while recovering an amount of protein exhibiting total inhibin activity equal to at least 90% of that of the crude extract.

Throughout the purification procedure, the inhibin bioactivity was monitored by an in vitro bioassay using rat anterior pituitary monolayer culture, Vale, W. et al. Endocrinology, 91, 562-572 (1972). In brief, 21-day-old female rat anterior pituitaries are collected, enzymatically dispersed and plated in 10% fetal bovine serum in HDMEM (GIBCO Laboratories, Santa Clara, CA.) into 24-well tissue culture plates (Falcon Plastic, Oxnard, CA.) on day 1. On day 2, the medium is

-9-

changed to 1% fetal bovine serum in HDMEM, and the sample is added. Incubation is continued for another 48 hours. The medium is then harvested, and the LH and FSH contents are determined by radio-immunoassay (RIA) using materials provided by The Pituitary Hormone Program of NIADDKD. In this assay, the inhibin proteins inhibit the basal release of FSH only but not that of LH, as compared to control cells that receive the incubation medium only.

For the detection of inhibin activity in the various column fractions, aliquots ranging from 0.01% to 0.1% by volume were removed, and after adding 100 µg human serum albumin in 100 µl water, the solvents were evaporated in a Speed-Vac concentrator (Savant, Hicksville, N.Y.). The residue was redissolved in 3 ml 1% fetal bovine serum in HDMEM, filtered through a Millex-GS 0.22 µm filter (Millipore Corp., Bedford, MA) and assayed in duplicate. To speed up the bioassays during the purification process, only basal inhibition of FSH secretion exerted by the inhibin activity was determined and plotted in the region where the inhibin proteins were expected to migrate in the chromatograms.

To perform the heparin-Sepharose affinity chromatography, a 500 ml bottle of frozen PFF was defrosted, and the cell debris were spun down in a Beckman J2-21 centrifuge (Beckman Instruments, Inc., Palo Alto, CA.) using a JA-20 rotor at 10,000 rpm for 30 minutes. One half of the supernatant (250 ml) was diluted to 10 times its volume by the addition of 2,250 ml of 0.01 M Tris-HCl containing 0.1 M NaCl, pH 7, in a 4 liter Erlenmeyer flask and pumped simultaneously via eight silastic tubes (0.76mm ID) into eight heparin-Sepharose (Pharmacia Fine Chemicals, Piscataway, N. J.) columns (3.5 x 9 cm) by two Rabbit 4-channel peristaltic pumps (Rainin Instrument Co., Inc., Emeryville, CA.) at 40 ml/hr per column. After all the fluid had been pumped through the heparin-Sepharose, the

-10-

eight columns were washed simultaneously with 3.5 liters of 0.01 M Tris-HCl, pH 7, containing 0.1 M NaCl in the same manner. The adsorbed proteins with inhibin activity were removed by washing the eight columns 5 simultaneously with 1.3 liters of 0.01 M Tris-HCl containing 1 M NaCl, pH 7, as above, and the wash was collected into fractions of 16 ml. Figure 1a shows a typical elution profile of the inhibin activity material from PFF. The inhibin activity was monitored by the in 10 vitro bioassay described above. The columns were regenerated by further washing with 1.6 liters 2M NaCl in 0.01 M Tris-HCl, pH 7, and re-equilibrated with 3.5 liters 0.01 M Tris-HCl containing 0.1 M NaCl for purification of the remaining 250 ml of PFF.

15 Next, the material was fractionated by gel filtration to separate proteins generally according to their molecular weights. The fractions having inhibin activity extracted by the eight heparin-Sepharose columns were pooled (400 ml) and dialyzed overnight to 20 remove NaCl in a 28.6 mm cylinder diameter Spectrapor No. 3 membrane tubing with M_r cutoff at 3,500 (Spectrum Medical Industries, Inc., Los Angeles, CA.) against 16 liters of 30% acetic acid. The retained fluid was centrifuged, as above, to remove a white 25 precipitate, and the supernatant was divided into eight equal portions for applying to eight 5 x 100 cm Sephadryl S-200 superfine columns (Pharmacia Fine Chemicals, Piscataway, N. J.). Each column was eluted with 30% acetic acid at 20 ml for 22 min., and the 30 column fractions were monitored by UV absorption at 280 nm and by bioassay.

Fig. 1b shows the elution profile of the inhibin material purified in a Sephadryl S-200 column. Two elution zones of approximately equal amounts of 35 activity were detected, one eluting at M_r about 30,000 and the other at M_r about 12,000. However, based upon the protein concentration as determined by UV

-11-

absorption, the low-molecular-weight zone contains much higher specific activity. As a result, this region was selected for further purification by RP-HPLC.

The low-molecular-weight inhibin protein from 5 the eight S-200 columns was pooled and lyophilized. The lyophilized material (40 mg) was dissolved in 40 ml 0.2N acetic acid and filtered through a Millex-HA 0.45 μm filter (Millipore Corp., Bedford, MA.). The filtrate was applied directly onto a 1 x 25 cm Vydac 5- μm particle-size C4 column (The Separations Group, Hesperia, CA.) and developed with a gradient of TEAP buffer as shown in Figure 1c. In the TEAP system, buffer A consists of 0.25 N. triethylammonium phosphate, pH 3, and buffer B is 80% acetonitrile in buffer A. 10 15 After all the filtrate had been loaded, the column was washed with the aqueous buffer A until the UV absorption reached baseline. The fractions exhibiting inhibin activity were separated in a Beckman 332 gradient liquid chromatography system (Beckman Instruments, Inc., 20 Berkely, CA.) equipped with a Spectroflow 757 UV detector (Kratos Analytical Instruments, Ramsey, N. J.), a Soltec 220 recorder (Soltec Corp., Sun Valley, CA.) and a Redirac 2112 fraction collector (LKB Instruments, Inc., Gathersburg, MD.). Two zones of substantial 25 inhibin activity were detected, with more activity exhibited by the earlier eluting zone (inhibin Protein A) than the later eluting zone (inhibin Protein B), see Figure 1c.

Inhibin Protein B from the various columns were 30 pooled and further purified by two more RP-HPLC steps. The first step uses a 1 x 25 cm Vydac 5- μm -particle-size C4 column and a trifluoroacetic acid (TFA) buffer system (Figs. 2a) and the second step employs a 1 x 25 cm Vydac 5- μm -particle-size Phenyl column and the TEAP buffer 35 system, as shown in Fig. 2b. In the TFA system, buffer A contains 1 ml trifluoroacetic acid in 999 ml water and buffer B is 1 ml trifluoroacetic acid in 199 ml water

-12-

and 800 ml acetonitrile. Finally, inhibin Protein B accumulated from a few batches was concentrated by RP-HPLC using a 0.46 x 25 cm Aquapore RP-300 10 μ m-particle-size column (Brownlee Labs., Santa Clara, CA.) and the TFA buffer system as shown in Fig. 2c. Altogether, a total of approximately 60 μ g of inhibin Protein B was purified from the 18 liters of PFF.

Inhibin Protein A from the various columns was pooled and further purified by two more RP-HPLC steps. 10 The first step uses a 1 x 25 cm Vydac 5- μ m-particle-size C4 column and a trifluoroacetic acid (TFA) buffer system (Figs. 5a) and the second step employs a 1 x 25 cm Vydac 5- μ m-particle-size Phenyl column and the TEAP buffer system, as shown in Fig. 5b. In the TFA system, buffer 15 A contains 1 ml trifluoracetic acid in 999 ml water and buffer B is 1 ml trifluoroacetic acid in 199 ml water and 800 ml acetonitrile. Finally, inhibin Protein A accumulated from a few batches were concentrated by RP-HPLC using a 0.46 x 25 cm Aquapore RP-300 10 μ m-particle-size column (Brownlee Labs., Santa Clara, CA.) and the TFA buffer system as shown in Fig. 5c. Altogether, a total of approximately 600 μ g of inhibin Protein A was purified from the 18 liters of PFF.

Amino acid analyses of the substantially 25 homogeneous inhibin Proteins A and B were performed as described in Bohlen P., et al. Anal. Biochem. 126 144-156 (1982), and the results are shown in Table 1 below.

-13-

TABLE 1

AMINO ACID COMPOSITION OF PURIFIED INHIBIN
PROTEIN FROM PORCINE FOLLICULAR FLUID

	<u>Amino Acid</u>	<u>Protein A*</u>	<u>Protein B*</u>
5	Asx	18.5 ± 1.6	21.0 ± 1.1
	Thr	11.5 ± 0.5	13.5 ± 0.6
	Ser	16.3 ± 1.4	18.1 ± 0.7
	Glx	21.3 ± 1.4	22.5 ± 0.5
	Gly	19.9 ± 1.9	22.4 ± 0.7
10	Ala	19.7 ± 1.4	22.0 ± 0.6
	Val	14.1 ± 1.8	14.4 ± 0.4
	Met	6.1 ± 0.4	5.8 ± 0.3
	Ile	14.6 ± 1.7	10.3 ± 0.2
	Leu	27.3 ± 2.1	27.8 ± 0.8
15	Tyr	10.7 ± 1.3	11.4 ± 0.4
	Phe	11.6 ± 1.4	10.0 ± 0.2
	His	14.1 ± 1.2	7.9 ± 0.6
	Trp	4.4 ± 0.3	3.9 ± 0.4
	Lys	11.9 ± 0.9	5.4 ± 0.2
20	Arg	13.9 ± 0.6	15.8 ± 0.4
	Cys**	14.4 ± 0.2	14.2 ± 0.9
	Pro	29.2 ± 0.9	29.6 ± 1.1

* Data corresponds to the mean + SD of four analyses and normalized to a protein of 32,000 daltons.

25 ** Cysteine was determined as cysteic acid after performic acid oxidation.

The inhibin Protein B from the final RP-HPLC purification was analyzed under reducing and non-reducing conditions in 1-mm-thick 15% acrylamide gel according to the method of Laemmli, V., Nature 227 680-685 (1970). The protein was revealed by silver staining reagent (BIO-RAD, Richmond CA.). The following molecular weight standards were used to calibrate the gel: bovine serum albumin ($M_r = 67,000$), ovalbumin ($M_r = 43,000$), alpha-chymotrypsinogen ($M_r = 25,700$) and

-14-

lysozyme (M_r = 14,500). In non-reducing condition, 2 µg of inhibin protein in 20 µl water was incubated with 20 µl sample buffer (0.152 M Tris-HCl, pH 6.8, containing 20% glycerol (V/V), 4% sodium dodecylsulfate and 0.04% bromphenol blue) for 1 hour at 37°C prior to loading onto the gel. The electrophoresis was performed at a constant 200 volts for 6 hours at room temperature. In reducing condition, 2 ug of protein was incubated, first with 20 µl of 0.02 M dithiothreitol for 15 min at 37°C and then 20 µl of sample buffer was added and the incubation continued for one more hour before the sample was applied to the gel. Electrophoresis was carried out as above, except that 0.005 M dithiothreitol was included in the electrophoretic buffer. On SDS-PAGE under non-reducing condition, inhibin Protein B showed a single band migrating at M_r 32,000 (See Figure 3a). Under reducing condition, inhibin Protein B separated into two bands, one migrating at M_r 18,000 and the other M_r 14,000 (See Figure 3b). Similar 20 electrophoresis of Protein A showed two such bands plus one at M_r 8,000 which was felt to possibly indicate the presence of impurity.

25 NH_2 -terminal sequence analyses of the 18K and 14K chains of 32K inhibin Proteins A and B were accomplished by first separating the two chains by SDS-PAGE under reducing conditions, followed by electro-blotting of the separated protein chains onto GF/C paper which was subsequently punched out for direct microsequencing. Briefly, each inhibin protein (12-15 µg) was electrophoresed on 0.5-mm-thick 15% acrylamide 30 gel (8 x 10 cm) under reducing condition, as described above. After electrophoresis, the gel was immediately washed 3 times with 0.5% NP-40 (Sigma Chemical Co., St. Louis, MO.) in 0.5% acetic acid at room temperature. 35 The gel was then placed between 2 sheets of trifluoracetic acid-activated GF/C paper (Whatman, Clifton, N.J.) which had been wet briefly with the

-15-

blotting buffer (2% acetic acid containing 0.5% NP-40). One more activated GF/C paper was placed on the cathode side in case the protein was not completely absorbed by the first paper. The outer surface of the GF/C paper
5 was protected by Whatman No. 3 filter paper, and the whole assembly inserted between two Scotch-Brite pads held together by a plastic grid (BIO-RAD, Richmond, CA). This was electrophoresed in the blotting buffer at a constant voltage of 60 V for 16 hours at 4°C to
10 transfer the positively charged proteins onto the GF/C paper. The electrolytically transferred protein chains were revealed with Coomassie blue staining. 1.2 cm diameter circles were punched out of the stained protein bands and subjected directly to microsequencing as
15 described above.

Microsequencing, as described in Esch, F. Anal. Biochem. 136, 39-47, 1984, of intact inhibin protein beginning at the NH₂-terminus had consistently revealed two residues of approximately equal
20 concentration at every cycle, indicating each protein is composed of two chains. Based upon the results from multiple sequencing analyses of both intact and reduced inhibin proteins, the NH₂-terminal residues of the 18K chain of each inhibin protein are Ser-Thr-Ala-Pro-Leu-
25 Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val. The NH₂-terminal residues of the 14K chain of inhibin Protein B are Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-, and
30 the NH₂-terminal residues of the 14K chain of inhibin Protein A are Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-.

Once a substantial portion of the sequence of
35 the three chains of inhibin protein are known, the mRNA encoding the chains can be isolated, and the cDNA's can be synthesized by recombinant DNA techniques. Messenger

-16-

RNA (mRNA) is obtained from ovarian follicles which produce inhibin, and then cDNA is synthesized from the mRNA by reverse transcription. The cDNA is inserted into a cloning vector which is used to transform a
5 suitable host to create a cDNA library.

Based upon the known partial amino acid residue sequences of the three inhibin chains, labelled oligonucleotides are synthesized for detecting cDNA corresponding to each chain. Because of the degeneracy
10 of the genetic code, mixed hybridization probes are prepared and used as probes. These probes are then used to select, from the library, cDNA clones that contain gene sequences encoding the chains. cDNA libraries may also be screened by immunological expression assay with
15 antibody raised against inhibin or one of the inhibin chains. Immunological expression assay may also be used to confirm screening with hybridization probes.

From selected clones, cDNA is excised and inserted into appropriate vectors under the control of
20 promotor sequences, and the vectors are transformed into cell lines for expression of the recombinant inhibin chains. Although vectors containing the genes for an appropriate pair of chains could conceivably be transformed into the same cell line, for simplicity,
25 vectors for expression of each chain are preferably transformed separately into cell lines. The individual inhibin chains can then be isolated from the cellular material and/or the cell culture medium and are useful as intermediates for the preparation of the bioactive
30 inhibin. Appropriate quantities of the 18K and the 14K chains are then subjected to oxidizing conditions which promote disulfide bonding between the chains to produce inhibin.

The foregoing molecular biology techniques may
35 also be used to read the gene sequences encoding the separate inhibin chains, and thereby completely characterize the protein chains. Protein A has now been

-17-

completely characterized and found to include a 134-residue chain (the 18K chain) that is linked by one or more disulfide bridges to a 116-residue chain (the 14K chain). The 134-residue chain has the following formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH. The 116-residue chain has the following formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH. This characterization is in agreement with the earlier analyses of the purified protein material obtained from PFF; the disparity between the number of residues in the first chain and the measured value of 18K is accounted for by the presence of the aforementioned glycosylation. It is believed that a carbohydrate moiety having a molecular weight of about 3000 daltons is attached to the side chain of the Asn residue in the 36-position of the first chain.

Protein B has also been characterized and the 18K chain is believed to have the same sequence as Protein A. The 14K chain has been found to have the following 115-residue formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-

-18-

Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-5 Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH. This characterization is in agreement with the earlier analyses of the purified protein material obtained from 10 PFF.

The invention thus provides polypeptides or relatively short proteins between about 115 residues and about 134 residues in length which are useful as intermediates to create disulfide-bonded dimers that are 15 biologically active. More specifically, the invention provides the three polypeptides set forth as follows:

(a) H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-20 Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-25 Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH; (b) H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-30 Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-35 Cys-Ala-OH and (c) H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-

-19-

Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-Asn-His-
5 Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH. For example,
10 the 134-residue polypeptides may be combined with one of the other shorter polypeptides to form biologically active disulphide-bonded heterodimers.

Substantially pure 32K inhibin or the nontoxic salts thereof, combined with a pharmaceutically acceptable carrier to form a pharmaceutical composition, 15 may be administered to mammals, including humans, either intravenously, subcutaneously, percutaneously, intramuscularly or orally for control of fertility. Administration of inhibin induces decreased fertility in female mammals and decreases spermatogenesis in male
20 mammals. Administration of a sufficient amount of inhibin induces infertility in mammals. Inhibin is also useful for tests to diagnose infertility.

Such peptides are often administered in the form of pharmaceutically acceptable nontoxic salts, such 25 as acid addition salts or metal complexes, e.g., with zinc, iron or the like (which are considered as salts for purposes of this application). Illustrative of such acid addition salts are hydrochloride, hydrobromide, sulphate, phosphate, maleate, acetate, citrate, benzoate, succinate, malate, ascorbate, tartrate and the like. If the active ingredient is to be administered in tablet form, the tablet may contain a binder, such as tragacanth, corn starch or gelatin; a disintegrating agent, such as alginic acid; and a lubricant, such as 30 magnesium stearate. If administration in liquid form is desired, sweetening and/or flavoring may be used, and intravenous administration in isotonic saline, phosphate buffer solutions or the like may be effected.

-20-

Inhibin should be administered under the guidance of a physician, and pharmaceutical compositions will usually contain an effective amount of the peptide in conjunction with a conventional, pharmaceutically-
5 acceptable carrier. The dosage will vary depending upon the specific purpose for which the protein is being administered, and dosage levels in the range of about 0.1 to about 1 milligrams per Kg. of body weight may be used when the protein is administered on a regular basis
10 as a male contraceptive.

Although the method of purification of inhibin has been described primarily in terms of isolation from PFF, inhibin can be similarly purified from other crude extracts. The term "crude extracts" as used herein
15 refers to other mammalian body material in addition to follicular fluid, as well as to extracts from organisms including laboratory microorganisms, such as prokaryotes (e.g. E. Coli) and eukaryotes (e.g. S. cerevisiae yeast), which have been transformed by means of state of the art
20 methodology to manufacture mammalian inhibin protein.

Although the invention has been described with regard to its preferred embodiments, which constitute the best mode presently known to the inventors, it should be understood that various changes and
25 modifications as would be obvious to one having the ordinary skill in this art may be made without departing from the scope of the invention which is set forth in the claims appended hereto.

Particular features of the invention are
30 emphasized in the claims which follow.

WHAT IS CLAIMED IS:

1. A 32,000-dalton protein having a purity of at least about 90% by weight of total proteins, said protein having a pKa of about 4.8, said protein being composed of a first polypeptide chain having a molecular weight of about 18,000 and a second polypeptide chain having a molecular weight of about 14,000 daltons, said first chain and said second chain being linked to each other through disulfide bonding in the active protein, said first chain having an amino-terminal sequence 5 beginning with Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val and said second chain having an amino-terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly, said protein specifically inhibiting basal secretion of 10 follicle-stimulating hormone while not inhibiting basal secretion of luteinizing hormone.
2. A protein according to claim 1 wherein said second chain has an amino terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu.
3. A protein according to claim 1 wherein 15 said second chain has an amino terminal sequence beginning with Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-X-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp, wherein X is an unknown amino acid residue.
4. A protein according to claim 1 wherein 20 said second chain has the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro.

-22-

5. A protein according to claim 1 wherein said second chain has the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-
5 Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-
10 Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH.

6. A protein according to Claim 1 having an amino acid composition of about Asx 21.0, Thr 13.5. Ser 18.1, Glx 22.5, Gly 22.4, Ala 22.0, Val 14.4, Met 5.8, Ile 10.3, Leu 27.8, Tyr 11.4, Phe 10.0, His 7.9, Trp 3.9, Lys 5.4, Arg 15.8, Cys 14.2, and Pro 29.6.

7. A protein according to Claim 1 having an amino acid composition of about Asx 18.5, Thr 11.5. Ser 16.3, Glx 21.3, Gly 19.9, Ala 19.7, Val 14.1, Met 6.1, Ile 14.6, Leu 27.3, Tyr 10.7, Phe 11.6, His 14.1, Trp 4.4, Lys 11.9, Arg 13.9, Cys 14.4, and Pro 29.2.

8. A protein according to Claim 1 wherein said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-
25 Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-
30 Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH and is glycosylated.

-23-

9. A protein according to Claim 5 wherein
said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-
Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-
Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-
5 Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-
Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-
Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-
Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Val-
10 Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-
Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-
Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-
Ala-Cys-Ile-OH.

10. A protein according to claim 1 wherein
said second chain has the formula:
15 H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-
Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-
Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-
Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-
Ser-Phe-His-Thr-Ala-Val-Val-Asn-Gln-Tyr-Arg-Met-Arg-Gly-
20 Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-
Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-
Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-
Gly-Cys-Ala-OH

11. A protein according to Claim 10 wherein
25 said first chain has the formula: H-Ser-Thr-Ala-Pro-Leu-
Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-
Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-
Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-
Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-
30 Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-
Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Val-
Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-
Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-
Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-
35 Ala-Cys-Ile-OH.

-24-

12. A method of obtaining substantially homogeneous proteins having inhibin activity from crude extracts comprising
procuring extract material having inhibin
5 activity,

exposing said extract to a support medium to which heparin moieties are attached under such conditions that inhibin proteins adsorb to said heparin moieties, and subsequently eluting said inhibin proteins
10 from said heparin moieties,

gel filtrating said eluted inhibin proteins and selecting fractions having inhibin activity, and fractionating said gel filtrated fractions on at least one reverse-phase high performance liquid
15 chromatography column.

13. A method according to Claim 12 wherein said gel filtrated fractions are fractionated on at least two successive reverse-phase high performance liquid chromatography columns of different solid and/or
20 liquid phase conditions.

14. A method according to Claim 12 wherein at least one of said RP-HPLCS is performed on a C3-C5 column.

15. A method according to Claim 12 wherein
25 said crude extract is obtained from porcine body material.

16. A method according to Claim 15 wherein said body material is porcine follicular fluid.

-25-

17. A synthetic protein produced by recombinant DNA techniques or the like having two chains interconnected by disulfide bonding, said first chain having formula: H-Ser-Thr-Ala-Pro-Leu-Pro-Trp-Pro-Trp-
5 Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-Val-Pro-Gly-Ala-Pro-
10 Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-Leu-Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-Cys-Ala-Cys-Ile-OH, and said second chain having either the formula: H-Gly-
15 Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-Asn-His-Tyr-Arg-Met-Arg-Gly-His-
20 Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH, or the formula H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-
25 Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-
30 Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH

-26-

18. A synthetic polypeptide useful as a chemical intermediate for the production of a biologically active dimer, which polypeptide is selected from the group consisting of: (a) H-Ser-Thr-Ala-Pro-
5 Leu-Pro-Trp-Pro-Trp-Ser-Pro-Ala-Ala-Leu-Arg-Leu-Leu-Gln-
Arg-Pro-Pro-Glu-Glu-Pro-Ala-Val-His-Ala-Asp-Cys-His-Arg-
Ala-Ser-Leu-Asn-Ile-Ser-Phe-Gln-Glu-Leu-Gly-Trp-Asp-Arg-
Trp-Ile-Val-His-Pro-Pro-Ser-Phe-Ile-Phe-His-Tyr-Cys-His-
Gly-Gly-Cys-Gly-Leu-Pro-Thr-Leu-Pro-Asn-Leu-Pro-Leu-Ser-
10 Val-Pro-Gly-Ala-Pro-Pro-Thr-Pro-Val-Gln-Pro-Leu-Leu-
Val-Pro-Gly-Ala-Gln-Pro-Cys-Cys-Ala-Ala-Leu-Pro-Gly-Thr-
Met-Arg-Ser-Leu-Arg-Val-Arg-Thr-Thr-Ser-Asp-Gly-Gly-Tyr-
Ser-Phe-Lys-Tyr-Glu-Thr-Val-Pro-Asn-Leu-Leu-Thr-Gln-His-
Cys-Ala-Cys-Ile-OH; (b) H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-
15 Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-
Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-
Tyr-Gly-Asn-Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-
Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-
Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-
20 Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-
Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-
Asn-Met-Ile-Val-Glu-Glu-Cys-Gly-Cys-Ala-OH and (c) H-Gly-
Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Gln-
Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-
25 Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-Tyr-Cys-Glu-Gly-Glu-
Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-
Phe-His-Ser-Thr-Val-Ile-Asn-His-Tyr-Arg-Met-Arg-Gly-His-
Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-
Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-
30 Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-Ile-Val-Glu-Glu-Cys-
Gly-Cys-Ser-OH.

-27-

19. A polypeptide according to Claim 18 having the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Arg-Thr-Asn-Leu-Cys-Cys-Arg-Gln-Gln-Phe-Phe-Ile-Asp-Phe-Arg-Leu-Ile-Gly-Trp-Ser-Asp-Trp-Ile-Ile-Ala-Pro-Thr-Gly-Tyr-Tyr-Gly-Asn-
5 Tyr-Cys-Glu-Gly-Ser-Cys-Pro-Ala-Tyr-Leu-Ala-Gly-Val-Pro-Gly-Ser-Ala-Ser-Ser-Phe-His-Thr-Ala-Val-Val-Asn-Gln-Tyr-Arg-Met-Arg-Gly-Leu-Asn-Pro-Gly-Thr-Val-Asn-Ser-Cys-Cys-Ile-Pro-Thr-Lys-Leu-Ser-Thr-Met-Ser-Met-Leu-Tyr-Phe-Asp-Asp-Glu-Tyr-Asn-Ile-Val-Lys-Arg-Asp-Val-Pro-Asn-Met-Ile-
10 Val-Glu-Glu-Cys-Gly-Cys-Ala-OH.

20. A polypeptide according to Claim 18 having the formula: H-Gly-Leu-Glu-Cys-Asp-Gly-Lys-Val-Asn-Ile-Cys-Cys-Lys-Lys-Gln-Phe-Phe-Val-Ser-Phe-Lys-Asp-Ile-Gly-Trp-Asn-Asp-Trp-Ile-Ile-Ala-Pro-Ser-Gly-Tyr-His-Ala-Asn-
15 Tyr-Cys-Glu-Gly-Glu-Cys-Pro-Ser-His-Ile-Ala-Gly-Thr-Ser-Gly-Ser-Ser-Leu-Ser-Phe-His-Ser-Thr-Val-Ile-Asn-His-Tyr-Arg-Met-Arg-Gly-His-Ser-Pro-Phe-Ala-Asn-Leu-Lys-Ser-Cys-Cys-Val-Pro-Thr-Lys-Leu-Arg-Pro-Met-Ser-Met-Leu-Tyr-Tyr-Asp-Asp-Gly-Gln-Asn-Ile-Ile-Lys-Lys-Asp-Ile-Gln-Asn-Met-
20 Ile-Val-Glu-Glu-Cys-Gly-Cys-Ser-OH.

1 / 5








FIG. 1a**FIG. 1b****FIG. 1c**

FIG. 2a**FIG. 2b****FIG. 2c**

3 / 5

FIG. 3



4 / 5







FIG. 4

FIG. 5a**FIG. 5b****FIG. 5c**

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US86/01505

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC		
TNT CL.4 C07K 7/06, 7/08, 7/10, 13/00, 15/00 US CL. 530/313, 324, 325, 326, 327, 328, 344		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
U.S.	530/313, 324, 325, 326, 327, 328, 344	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁰ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X	US, N, <u>Biochemical & Biophysical Research Communication</u> , Published 14 JUNE 1985, Vol. 129, No. 2, MIYAMOTO et al "Isolation of Porcine Follicular Fluid Inhibin of 32K Daltons," pages 396-403.	1-20
A	US, N, <u>Archives of Andrology</u> , Published 13 DECEMBER 1984, Vol. 13, CHANNING et al "Porcine Inhibin: Initial Fractionation as a High Molecular Weight Complex," p. 2194231.	1,12-16
A	US, N, <u>Journal of Chromatography</u> , Published 1984, Vol. 288, RIVIER et al "Reversed-Phase High-Performance Liquid Chromatography Preparative Purification of Synthetic Peptides," pp. 303-328.	1,12-16
A	US, N, <u>Biology of Reproduction</u> , Published 1986, Vol. 34, MILLS et al "The Effects of Porcine Follicular Fluid Inhibin on Gonadotropin Secretion in the Rabbit," pp. 336-343.	1
* Special categories of cited documents: ¹⁵ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed		
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
12 AUGUST 1986	29 AUG 1986	
International Searching Authority ¹	Signature of Authorized Officer ¹⁹	
ISA/US	Nathan M. Nutter NATHAN M. NUTTER	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category ¹⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No ¹⁸
A	US, P, <u>Chem Abst.</u> 103: 65074s, Published 02 SEPTEMBER 1985, Vol. 103, No. 9 "Isolation From Porcine Follicular Fluid of a Potent Inhibin-like Biological Activity," RIVIER et al.	1-20

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.